

Correction: *Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection*

Hall EM, Yin DE, Goyal RK, *et al.* Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection. *J Immunother Cancer* 2021;9:e001225. doi: 10.1136/jitc-2020-001225

This article has been corrected since it first published. The provenance and peer review statement has been added.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2021;9:e001225corr1. doi:10.1136/jitc-2020-001225corr1

